Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kakehi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kakehi, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:1-5 (2003)
© 2003 Foundation for Promotion of Cancer Research

Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era

Yoshiyuki Kakehi+

Department of Urology, Faculty of Medicine, Kagawa Medical University, Kita-gun, Kagawa, Japan

ABSTRACT

The incidence rate of early-stage prostate cancer has dramatically increased since the introduction of the widespread use of PSA testing in developed countries, including Japan. With the downward stage migration there has been much interest in the concept of watchful waiting not only for elderly patients with a life expectancy of less than 10 years but also in younger patients with good social and sexual activity. The results of a recent randomized comparison between radical prostatectomy and watchful waiting for localized disease indicated comparable overall survival but superiority of surgery in disease-specific survival. The predictive value of clinico-pathological parameters including biopsy features and serum PSA seems insufficient to predict tumor growth potential. Our ongoing prospective study is aimed at clarifying whether PSA doubling time assessment for 6 months in patients with favorable biopsy features can be a good indicator for further watchful waiting or immediate aggressive treatment without any survival disadvantage.

FOOTNOTES

+ For reprints and all correspondence: Yoshiyuki Kakehi, Department of Urology, Faculty of Medicine, Kagawa Medical University, 1750–1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761–0793, Japan. E-mail: kakehi@kms.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Ang, M. Lijovic, L. K. Ashman, K. Kan, and A. G. Frauman
CD151 Protein Expression Predicts the Clinical Outcome of Low-Grade Primary Prostate Cancer Better than Histologic Grading: A New Prognostic Indicator?
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1717 - 1721.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.